Piper Sandler Maintains Overweight on Axonics, Raises Price Target to $77
Piper Sandler analyst Adam Maeder maintains Axonics (NASDAQ:AXNX) with a Overweight and raises the price target from $75 to $77.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Axonics Announces Launch Of Axonics F15 Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Wolfe Research Initiates Coverage On Axonics with Outperform Rating, Announces Price Target of $69
Wolfe Research analyst Mike Polark initiates coverage on Axonics (NASDAQ:AXNX) with a Outperform rating and announces Price Target of $69.
Axonics Receives FDA Approval For Recharge-Free Sacral Neuromodulation System
Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug